m~~c~’c,fr,t~
    ~
    rr77
    ~
    iJ
    October29, 2003
    RECEJIVED
    CLERK’S
    OFFICE
    OCT
    30
    ~OO3
    Charles E. Matoesian
    STATE OF IWNOIS
    Division ofLegal Counsel
    Pollution
    Control Board
    Illinois Environmental Protection Agency
    1021 North Grand Avenue East
    POBox
    19276
    Springfield,
    Illinois 62794
    Re: Wallace v. IEPA, PCB 02-207 (Air Variance)
    Dear Mr. Matoesian,
    As per condition 3.h. ofthe Order granting a variance in the
    above referenced matter,
    MedPointe Healthcare, Inc. is submitting this letter as a progress report for the period
    from April
    1, 2003 through
    September 30, 2003.
    As noted previously, the Wallace
    Pharmaceuticals’ name has been changed to MedPointe Pharmaceuticals.
    According to the Order, MedPointe is required to report on the progress ofthe
    development of a suitable alternative to the
    usage ofethanol in the affected processes.
    During the above referenced period, we were installing new air handling equipment in the
    tablet production area, and the tabletproduction area was idle from March through early
    June.
    As a result, we outsourced the development and production oftwo new tablet
    products that were recently introduced to the market.
    In the event that manufacture of
    these products is transferred back to Decatur in the future, we are pleased to report that
    their direct-compression manufacturing processes do not involve the use ofethanol.
    These research efforts should satisfy both conditions 3.a.
    and 3.b. ofthe Order, in that the
    bench-top, pilot, and
    commercial scale processes were successful for these products, and
    do not utilize VOM solvents.
    As we reported last April, a dry granulation process which uses no ethanol is in use for
    Tussi
    12-D Tablets, a new product launched by MedPointe in 2002.
    We expect to
    continue further evaluation ofthe dry granulation processes and substitute, where
    possible, for the ethanol-based wet granulation process.
    We continue our research efforts with emphasis being placed on non-VOM products and
    processes for our future product development. These efforts should not only minimize
    our VOM emissions but quite possibly keep them well within our pre-variance levels.
    In
    light ofthe items mentioned above, it is
    likely that add-on control technology may not be
    necessary to achieve compliance with our pre-variance limits of 12.5 tons per year.
    434 North Morgan Street, Decatur, IL 62523-1125
    217-424-8400
    www.medpointepharma.corn
    -2-
    At this writing, we expect our VOM emissions to be
    well below the allowable variance
    limit of 25 tons per year.
    I trust this briefletter report satisfies the Order requirement for a progress report. Ifany
    additional information is required please advise.
    Sincerely,
    William J.
    araszewski, Ph.D.
    Director, Pharmaceutical Production
    cc:
    Dorothy Gunn, Clerk
    Illinois Pollution Control Board
    State ofIllinois
    Center
    100 West Randolph St., Suite 11-500
    Chicago, IL
    60601

    Back to top